(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of 245.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Tscan Therapeutics's revenue in 2025 is $2,816,000.On average, 3 Wall Street analysts forecast TCRX's revenue for 2025 to be $620,572,816, with the lowest TCRX revenue forecast at $164,112,818, and the highest TCRX revenue forecast at $1,131,812,540. On average, 3 Wall Street analysts forecast TCRX's revenue for 2026 to be $807,718,019, with the lowest TCRX revenue forecast at $141,476,568, and the highest TCRX revenue forecast at $1,188,403,167.
In 2027, TCRX is forecast to generate $8,230,540,791 in revenue, with the lowest revenue forecast at $4,184,310,960 and the highest revenue forecast at $12,276,827,212.